Erik Faber MD PhD (@fabermdphd) header
Erik Faber MD PhD (@fabermdphd) profile picture

Onc fellow @MSKCancerCenter w/ #PDAC #GIOnc interest | #medchem 💊 PhD | 🐶 dad | @OslerResidency @umnmstp @dartmouth alum | 🏳️‍🌈 he/him | #mdphd

New York, NY
Joined July 2019
Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)
Erik Faber MD PhD retweeted
In one of the hardest NCI funding cycles in decades, these institutions captured the most research $ This is the map of where funds flowed in 2026 (full FY'26 dataset in 🧵 below..) How much of an institution's scientific identity can you infer from the mechanisms that got funded? ▪️MSK & MD Anderson tied at ~$128M each, but their portfolios look remarkably different ▫️Mount Sinai stands out for its unusually large U-series portfolio ▫️ UCSF & Dana-Farber have substantial center/program funding What are you seeing? - - - - - Source: NIH RePORTER via @Jori_health - - - - -
2
14
1
49
15,644
Erik Faber MD PhD retweeted
The best part of #AACRPanc26: the people. 💜  Mentors and mentees. Friends and collaborators. Scientists, clinicians and patient advocates. Different perspectives, one ☝️united front🛡️against #PancreaticCancer. Science brings us together. Friendship and shared purpose keep us moving forward. Grateful for this community. @AACR #PDAC #KRAS #TeamScience 💜 @MSK_DeptOfMed @MSKCancerCenter @CpcrMsk @PanCAN @lustgartenfdn @NatPancFdn @Pankind_Aus @EileenMOReilly @Jonathanwlee23 @BenWestphalen @GIcancerDoc Collin Weekes @OncoDailyGI @oncodaily
6
32
1,434
Erik Faber MD PhD retweeted
The National Science Foundation (NSF) has issued a 10-page memo signaling a retreat from its traditional role of giving grants to individual researchers to pursue their best ideas and to train the next generation of scientists. Instead, the memo makes clear, NSF will devote the bulk of its resources to addressing the research priorities of President Donald Trump and his administration, many of them technology focused. scim.ag/4ipE1kY
78
409
161
1,021
568,401
Erik Faber MD PhD retweeted
Among patients with previously untreated metastatic #ColorectalCancer, adding high-dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival compared with standard-dose vitamin D3. Objective response and overall survival were also similar between groups. ja.ma/4yfVsZT
1
11
36
10,003
Erik Faber MD PhD retweeted
The association of COVID vax, ICI, and improved survival was too good to be true: “the previously reported vaccination survival advantage is largely explained by selection bias, with patients who had more favorable prognoses more likely to receive the SARS-CoV-2 vaccination…”
Now online: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival doi.org/10.1158/2159-8290.CD…
3
1
5
2,114
Erik Faber MD PhD retweeted
Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide therapy was similar to that with indefinite therapy. Adverse events and second cancers were more common with indefinite therapy. Full phase 3 ENDURANCE trial results: nej.md/3TlfOlb Editorial: Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma nej.md/4wo0Iu9
3
24
4
58
28,457
Erik Faber MD PhD retweeted
Among patients with multivessel coronary artery disease who were in stable condition 1 year after stenting, an additional year of DAPT led to a lower risk of ischemic events than aspirin alone, without increased bleeding. Full DAPT-MVD trial results: nej.md/4wLDIox Editorial: Balancing the Scales — Extended DAPT in Coronary Artery Disease nej.md/4gAVqpZ
3
79
4
223
30,676
The @US_FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial #sarcoma. The clinical trials resulting in the drug’s approval were led by MSK sarcoma specialist and immunotherapy expert Dr. @sandrapdangelo. “This treatment offers a meaningful new option for people with this rare cancer,” Dr. D’Angelo says. “It is also an important step forward in the development of T cell therapies for solid tumors, which has been a major challenge.” Read more about this treatment: bit.ly/4fvX36j
4
12
1
47
4,596
Erik Faber MD PhD retweeted
Online Now: Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts dlvr.it/TTD0f7
51
1
157
11,437
🚨RETRACTED 🫨 👇Retraction note nature.com/articles/s41591-0…
⚠️Update: Following “social media peer review,” the journal posted an Editor’s Note and is investigating concerns about protocol/registration and findings. Outcome pending → possible correction/retraction depending on the investigation. SNS検証を受けて編集部が注意喚起+調査開始で結論待ち(訂正/撤回の可能性も?)
2
23
5
60
30,270
Erik Faber MD PhD retweeted
Now in @CD_AACR: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-related Survival - by Justin Jee, @SawyersLabMSKCC, @nikolausschultz, et al. @MSKCancerCenter - these findings suggest that the previously reported survival advantage may be explained by selection bias.
Now online: Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival doi.org/10.1158/2159-8290.CD…
2
7
1
19
9,425
Congratulations to MSK gastrointestinal medical oncologist @EileenMOReilly on being honored with the Hope Through Compassion Award from the @lustgartenfdn. The award recognizes her dedication to patients and her leadership in developing innovative clinical research for #pancreaticcancer. Watch to learn more about her approach to advancing pancreatic cancer research: bit.ly/3Qyo3cL
2
20
1
41
5,729
Erik Faber MD PhD retweeted
Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO
52
2,039
444
5,557
2,634,863
Erik Faber MD PhD retweeted
In a phase 1–2 study of daraxonrasib, treatment-related adverse events of grade 3 or higher occurred in 30% of patients with previously treated RAS-mutated pancreatic cancer, and up to 35% of patients had an objective response. Full study results: nej.md/4f7xfhX Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer nej.md/4neOTCE
1
46
7
122
30,102
Dr. Charles Sawyers speaks at #AACR26 Plenary Session about overcoming resistance through an approach that addresses lineage plasticity in prostate and other tumors. He recounted Enzalutamide, discussed elegant genetic mouse models of neuroendocrine prostate cancer involving PTEN, p53, and Rb. He then described a next-gen organoid based transplantation model of neuroendocrine prostate cancer (Romero et al Nature Cancer 2024). He described insights into organoids growth conditions, ECM, integrins and neuroendocrine transitions. YAP1/TAZ, TEAD, and hippo signaling gave insights to therapeutic intervention to reverse neuroendocrine differentiation. LATS, TEAD, and Notch inhibitors have been emerging from the organoid approach. Sustained YAP/TEAD, Notch and AR inhibition with Enzalutamide drove NEPC differentiation in vitro. Altered TEAD and FOXA1 binding occurs towards NEPC specific enhancers. DLL3 and LATS inhibitor were proposed for lineage restoration therapy.
1
8
18
2,218
Erik Faber MD PhD retweeted
🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…
20
231
38
730
258,808
Erik Faber MD PhD retweeted
New in the April 1 issue from the Cancer Research special series: Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer doi.org/10.1158/0008-5472.CA… @arnavmehta3 @centralparkwmd @EileenMOReilly @ciacobu @dana_peer #OpenAccess
4
22
4
43
17,681